Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Aytu Biopharma (AYTU) Receivables - Other (2021)

Aytu Biopharma has reported Receivables - Other over the past 1 years, most recently at $9000.0 for Q3 2021.

Quarterly Receivables - Other changed N/A to $9000.0 in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $9000.0 through Sep 2021, changed N/A year-over-year, with the annual reading at $21000.0 for FY2021, N/A changed from the prior year.
Receivables - Other was $9000.0 for Q3 2021 at Aytu Biopharma, down from $21000.0 in the prior quarter.
Over five years, Receivables - Other peaked at $21000.0 in Q2 2021 and troughed at $9000.0 in Q3 2021.